Study Protocol: Randomised Controlled Trial Assessing the Efficacy of Strategies Involving Self-Sampling in Cervical Cancer Screening

Int J Public Health. 2022 Feb 24:67:1604284. doi: 10.3389/ijph.2022.1604284. eCollection 2022.

Abstract

Objectives: The cervical cancer screening coverage remains moderate (60%) in France. The aim of the study is to evaluate the efficacy of two experimental invitation strategies (offer of urine or vaginal self-sampling kits) to reach under-screened populations and compare them with the current invitation strategy in rural departments (low medical density and low participation rate) in France. Methods: The study is a randomised controlled trial with three arms: a control arm (conventional invitation letter) and two experimental arms (mailing of a urine or vaginal self-sampling kit). The target population includes women aged 30-65 years, who had no screening test recorded since more than 4 years and who did not respond to an invitation letter within 12 months before. The primary outcome measure is the participation rate in each arm. A team of psychologists will also investigate attitudes and experiences by semi-structured/focus-group interviews with voluntary CapU4 participants and with health professionals. Result and conclusion: CapU4 will identify effective strategies to reach women not responding to current screening invitations and will generate information about acceptance of self-sampling among women and health professionals.

Keywords: cancer screening test; cervical cancer; randomised controlled trial; screening coverage; semi-structured interviews; under-screened women; urinary self-sampling; vaginal self-sampling.

Publication types

  • Clinical Trial Protocol

MeSH terms

  • Adult
  • Aged
  • Early Detection of Cancer
  • Female
  • Humans
  • Middle Aged
  • Randomized Controlled Trials as Topic
  • Self Care
  • Specimen Handling
  • Uterine Cervical Neoplasms* / diagnosis
  • Uterine Cervical Neoplasms* / epidemiology
  • Uterine Cervical Neoplasms* / prevention & control
  • Vaginal Smears

Grants and funding

This study has received support from the French National Cancer Institute (INCa) (attribution number 2021-158; INCA_16317) for the CapU4 study.